Respiratory disease is a core therapeutic area for this sponsor. When it announced the start of its Phase III program for its compound as a potential treatment for severe uncontrolled asthma, the sponsor was facing a crowded field. There were four other products in Phase III and multiple products in Phase II. Because this class of drug was in a race to approval, keeping the program on track and filing a BLA as quickly as possible were paramount.
Breathe easier with Acurian.
Acurian has developed multi-tactic campaigns to support: asthma, bronchiectasis, COPD, emphysema, grass pollen-induced rhinoconjunctivitis, idiopathic pulmonary fibrosis, pediatric common cold, pulmonary arterial hypertension, and upper respiratory infection.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.